$47.13
4.86% today
Nasdaq, May 21, 06:17 pm CET
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Bio-Techne Corporation Target price 2025 - Analyst rating & recommendation

Bio-Techne Corporation Classifications & Recommendation:

Buy
65%
Hold
35%

Bio-Techne Corporation Price Target

Target Price $66.70
Price $49.53
Potential
Number of Estimates 10
10 Analysts have issued a price target Bio-Techne Corporation 2026 . The average Bio-Techne Corporation target price is $66.70. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 11 Analysts recommend Bio-Techne Corporation to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Bio-Techne Corporation stock has an average upside potential 2026 of . Most analysts recommend the Bio-Techne Corporation stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Jun '24 2025
Estimates
Revenue Billion $ 1.16 1.22
1.97% 5.06%
EBITDA Margin 24.30% 34.49%
15.48% 9.60%
Net Margin 14.20% 11.23%
41.49% 20.92%

12 Analysts have issued a sales forecast Bio-Techne Corporation 2025 . The average Bio-Techne Corporation sales estimate is

$1.2b
Unlock
. This is
0.74% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.2b 1.79%
Unlock
, the lowest is
$1.2b 0.18%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $1.2b 1.97%
2025
$1.2b 5.06%
Unlock
2026
$1.3b 5.96%
Unlock
2027
$1.4b 8.42%
Unlock
2028
$1.7b 18.42%
Unlock

11 Analysts have issued an Bio-Techne Corporation EBITDA forecast 2025. The average Bio-Techne Corporation EBITDA estimate is

$420m
Unlock
. This is
10.05% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$425m 29.16%
Unlock
, the lowest is
$411m 24.91%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $282m 13.81%
2025
$420m 15.13%
Unlock
2026
$457m 8.76%
Unlock
2027
$511m 11.89%
Unlock
2028
$663m 29.73%
Unlock

EBITDA Margin

2024 24.30% 15.48%
2025
34.49% 9.60%
Unlock
2026
35.40% 2.64%
Unlock
2027
36.53% 3.19%
Unlock
2028
40.02% 9.55%
Unlock

5 Bio-Techne Corporation Analysts have issued a net profit forecast 2025. The average Bio-Techne Corporation net profit estimate is

$137m
Unlock
. This is
6.34% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$144m 12.20%
Unlock
, the lowest is
$119m 7.32%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $165m 40.34%
2025
$137m 16.96%
Unlock
2026
$195m 42.78%
Unlock
2027
$289m 47.90%
Unlock
2028
$317m 9.70%
Unlock

Net Margin

2024 14.20% 41.49%
2025
11.23% 20.92%
Unlock
2026
15.12% 34.64%
Unlock
2027
20.63% 36.44%
Unlock
2028
19.11% 7.37%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Jun '24 2025
Estimates
Earnings Per Share $ 1.05 0.87
40.34% 17.14%
P/E 56.80
EV/Sales 6.61

5 Analysts have issued a Bio-Techne Corporation forecast for earnings per share. The average Bio-Techne Corporation EPS is

$0.87
Unlock
. This is
6.10% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.92 12.20%
Unlock
, the lowest is
$0.76 7.32%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $1.05 40.34%
2025
$0.87 17.14%
Unlock
2026
$1.25 43.68%
Unlock
2027
$1.84 47.20%
Unlock
2028
$2.02 9.78%
Unlock

P/E ratio

Current 60.37 13.10%
2025
56.80 5.91%
Unlock
2026
39.78 29.96%
Unlock
2027
26.90 32.38%
Unlock
2028
24.52 8.85%
Unlock

Based on analysts' sales estimates for 2025, the Bio-Techne Corporation stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.66 43.27%
2025
6.61 0.77%
Unlock
2026
6.24 5.63%
Unlock
2027
5.75 7.77%
Unlock
2028
4.86 15.55%
Unlock

P/S ratio

Current 6.42 43.86%
2025
6.38 0.74%
Unlock
2026
6.02 5.63%
Unlock
2027
5.55 7.77%
Unlock
2028
4.69 15.55%
Unlock

Current Bio-Techne Corporation Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
UBS
Locked
Locked
Locked May 09 2025
Benchmark
Locked
Locked
Locked May 08 2025
RBC Capital
Locked
Locked
Locked May 08 2025
Stifel
Locked
Locked
Locked May 08 2025
Keybanc
Locked
Locked
Locked Apr 09 2025
Keybanc
Locked
Locked
Locked Apr 08 2025
Evercore ISI Group
Locked
Locked
Locked Mar 18 2025
Analyst Rating Date
Locked
UBS:
Locked
Locked
May 09 2025
Locked
Benchmark:
Locked
Locked
May 08 2025
Locked
RBC Capital:
Locked
Locked
May 08 2025
Locked
Stifel:
Locked
Locked
May 08 2025
Locked
Keybanc:
Locked
Locked
Apr 09 2025
Locked
Keybanc:
Locked
Locked
Apr 08 2025
Locked
Evercore ISI Group:
Locked
Locked
Mar 18 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today